Kripthonite Therapeutics ApS: Financial statements 2025
CVR: 43770209
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Kripthonite Therapeutics ApS (CVR 43770209) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -3,512,912 and a net result of DKK -3,936,274 compared with DKK -32 the year before. Equity in the 2025 report amounted to DKK 4,598,287. The solvency ratio was 95.9%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -3,512,912
- Profit/Loss
- DKK -3,936,274
- Equity
- DKK 4,598,287
- Total Assets
- DKK 4,793,259
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -3.5 mio. | -3.9 mio. | 4.6 mio. | 1 |
| 2024 | - | 125 t. | -32 | 35 t. | 1 |
| 2023 | - | 542 t. | -5 t. | 35 t. | 1 |
Official annual report
How creditworthy is Kripthonite Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of November 1, 2025, Sønderup Godkendt Revisionsaktieselskab has been appointed auditor of Kripthonite Therapeutics ApS.
As of November 1, 2025, Revisionsfirmaet Tom Sønderup I/S has stepped down as auditor of Kripthonite Therapeutics ApS.
As of November 1, 2025, Marigold Maturation Fund K/S is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 15%.
As of October 1, 2025, Peter Horn Møller has joined the board of directors of Kripthonite Therapeutics ApS.
As of October 1, 2025, Søren Bregenholt Frederiksen has joined the board of directors of Kripthonite Therapeutics ApS.
As of September 30, 2025, Peter Horn Møller has left the board of directors of Kripthonite Therapeutics ApS.
Kripthonite Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK 125,449, and the net result was DKK -32.
As of May 1, 2025, Marigold Innovation ApS is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 20%.
As of May 1, 2025, Thomas B. Poulsen Holding ApS is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 20%.
As of May 1, 2025, Hjerrild Chemistry Consulting ApS is registered as an owner of Kripthonite Therapeutics ApS with an ownership share of 20%.
About Kripthonite Therapeutics ApS
Kripthonite Therapeutics ApS is a Danish company of the type Anpartsselskab based in Aarhus N, founded in 2023. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Jan Stenvang. The board consists of Søren Bregenholt Frederiksen (chair), Erik Vinther, Kristian Mark Jacobsen and Per Hjerrild. The company's owners include Marigold Innovation ApS, Thomas B. Poulsen Holding ApS and Hjerrild Chemistry Consulting ApS. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK -3,512,912 and a net result of DKK -3,936,274 compared with DKK -32 the year before. Equity in the 2025 report amounted to DKK 4,598,287.